First Eagle Investment Management LLC decreased its position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 50.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,606 shares of the medical research company’s stock after selling 7,606 shares during the quarter. First Eagle Investment Management LLC’s holdings in Quest Diagnostics were worth $1,773,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Cibc World Market Inc. lifted its stake in Quest Diagnostics by 28.5% in the third quarter. Cibc World Market Inc. now owns 9,623 shares of the medical research company’s stock valued at $2,243,000 after acquiring an additional 2,135 shares during the last quarter. HighTower Advisors LLC raised its position in shares of Quest Diagnostics by 0.6% in the third quarter. HighTower Advisors LLC now owns 68,110 shares of the medical research company’s stock valued at $15,874,000 after purchasing an additional 418 shares during the period. Intech Investment Management LLC raised its position in shares of Quest Diagnostics by 13.3% in the third quarter. Intech Investment Management LLC now owns 23,090 shares of the medical research company’s stock valued at $5,382,000 after purchasing an additional 2,715 shares during the period. Virtus Advisers LLC bought a new position in shares of Quest Diagnostics in the third quarter valued at about $125,000. Finally, Trillium Asset Management LLC lifted its stake in shares of Quest Diagnostics by 0.6% during the 3rd quarter. Trillium Asset Management LLC now owns 25,798 shares of the medical research company’s stock worth $6,013,000 after buying an additional 154 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors.
Quest Diagnostics Stock Performance
Shares of NYSE:DGX opened at $258.20 on Friday. Quest Diagnostics Incorporated has a 12-month low of $171.18 and a 12-month high of $263.19. The company’s 50 day moving average price is $243.63 and its two-hundred day moving average price is $217.45. The firm has a market cap of $28.41 billion, a PE ratio of 25.72, a PEG ratio of 2.35 and a beta of 0.55. The company has a quick ratio of 1.58, a current ratio of 1.70 and a debt-to-equity ratio of 0.70.
Quest Diagnostics (NYSE:DGX – Get Free Report) last released its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.87 by $0.13. Quest Diagnostics had a net margin of 9.53% and a return on equity of 16.21%. The company had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the previous year, the business earned $2.60 earnings per share. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. Equities research analysts predict that Quest Diagnostics Incorporated will post 11.29 earnings per share for the current year.
Quest Diagnostics Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 27th. Investors of record on Tuesday, January 12th will be given a dividend of $0.86 per share. The ex-dividend date of this dividend is Tuesday, January 12th. This represents a $3.44 dividend on an annualized basis and a yield of 1.3%. Quest Diagnostics’s dividend payout ratio is currently 34.26%.
Insider Activity
In other Quest Diagnostics news, CAO Michael Deppe sold 11,776 shares of the firm’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $260.17, for a total transaction of $3,063,761.92. Following the transaction, the chief accounting officer owned 35,203 shares in the company, valued at $9,158,764.51. This trade represents a 25.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patrick Plewman sold 11,717 shares of Quest Diagnostics stock in a transaction on Monday, November 9th. The shares were sold at an average price of $257.34, for a total value of $3,015,252.78. Following the completion of the transaction, the senior vice president directly owned 14,684 shares of the company’s stock, valued at $3,778,780.56. This represents a 44.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 79,478 shares of company stock worth $19,794,031. 0.88% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Several analysts recently commented on the stock. Truist Financial lifted their target price on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock a “hold” rating in a report on Monday, September 21st. Mizuho increased their price target on shares of Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Weiss Ratings raised shares of Quest Diagnostics from a “buy (a)” rating to a “buy (a+)” rating in a report on Wednesday, October 21st. Argus set a $260.00 price objective on shares of Quest Diagnostics in a research report on Wednesday, July 29th. Finally, Barclays boosted their price objective on Quest Diagnostics from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, Quest Diagnostics currently has a consensus rating of “Moderate Buy” and an average price target of $248.70.
About Quest Diagnostics
Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.
Read More
- Five stocks we like better than Quest Diagnostics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
